drugset / Trial / NCT01494727

Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg

NCT01494727

Phase 1 Completed 48 enrolled HK inno.N Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

The objectives of this study are: * To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers * To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers

Timeline

Start
2012-02
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg Oral
Comparator Valsartan Small molecule 160 mg Oral

Indications

No indication recorded.